Enhanced characterization of breast cancer phenotypes using Raman micro-spectroscopy on stainless steel substrate

Thomas, Giju; Fitzgerald, Sean; Gautam, Rekha; Chen, Fuyao; Haugen, Ezekiel; Rasiah, Pratheepa Kumari; Adams, Wilson R.; Mahadevan‐Jansen, Anita

doi:10.1039/d2ay01764d

Cited by 2 publications

(4 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the Raman bands at 1080-90cm − 1 and 1453cm − 1 , corresponding to phospholipids, display higher intensity in HER2 overexpressing SKBR3 cells than other lower HER2-expressing cells. It is tempting to correlate this spectral evidence with enhanced de-novo lipogenesis associated with HER2 signaling [45]. In line, triple negative cells (MDA-468) display a not-so-high level of lipids while, in sharp contrast, a huge increment of aromatic amino acids.…”

Section: Raman Characterization Of the Normal And Breast Cancer Cell ...mentioning

confidence: 99%

“…Speci c HER2-enriched Raman ngerprints have not been exhaustively investigated so far and, even in the positive cases, the results are poor or deprived of biophysics characterization. In this context, only a comparative study conducted on the e cacy of lapatinib, a tyrosine kinase inhibitor reports how HER2 expression impacts the Raman ngerprint in triple negative or HER2 + BC cell lines [18,45].…”

Section: -880mentioning

confidence: 99%

See 1 more Smart Citation

Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines

Spaziani,

Esposito,

Barisciano

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Breast cancer (BC) is a heterogeneous neoplasm characterized by several subtypes. One of the most aggressive with high metastasis rates presents overexpression of the human epidermal growth factor receptor 2 (HER2). A quantitative evaluation of HER2 levels is essential for a correct diagnosis, selection of the most appropriate therapeutic strategy and monitoring the response to therapy. Results In this paper, we propose the synergistic use of SERS and Raman technologies for the identification of HER2 expressing cells and its accurate assessment. To this end, we selected SKBR3 and MDA-MB-468 breast cancer cell lines, which have the highest and lowest HER2 expression, respectively, and MCF10A, a non-tumorigenic cell line from normal breast epithelium for comparison. The combined approach provides a quantitative estimate of HER2 expression and visualization of its distribution on the membrane at single cell level, clearly identifying cancer cells. Moreover, it provides a more comprehensive picture of the investigated cells disclosing a metabolic signature represented by an elevated content of proteins and aromatic amino acids. We further support these data by silencing the HER2 gene in SKBR3 cells, using the RNA interference technology, generating stable clones further analyzed with the same combined methodology. Significant changes in HER2 expression are detected at single cell level before and after HER2 silencing and the HER2 status correlates with variations of fatty acids and downstream signalling molecule contents in the context of the general metabolic rewiring occurring in cancer cells. Specifically, HER2 silencing does reduce the growth ability but not the lipid metabolism that, instead, increases, suggesting that higher fatty acids biosynthesis and metabolism can occur independently of the proliferating potential tied to HER2 overexpression. Conclusions Our results clearly demonstrate the efficacy of the combined SERS and Raman approach to definitely pose a correct diagnosis, further supported by the data obtained by the HER2 gene silencing. Furthermore, they pave the way to a new approach to monitor the efficacy of pharmacologic treatments with the aim to tailor personalized therapies and optimize patients’ outcome.

show abstract

Section: Raman Characterization Of the Normal And Breast Cancer Cell ...mentioning

confidence: 99%

Section: -880mentioning

confidence: 99%

Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines

Spaziani,

Esposito,

Barisciano

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…In contrast, the Raman bands at 1080-90 cm − 1 and 1453 cm − 1 , corresponding to phospholipids, display higher intensity in HER2 overexpressing SKBR3 cells than other lower HER2-expressing cells. It is tempting to correlate this spectral evidence with enhanced de-novo lipogenesis associated with HER2 signaling [48]. In line, triple negative cells (MDA-468) display a not-so-high level of lipids while, in sharp contrast, a huge increment of aromatic amino acids.…”

Section: Raman Characterization Of the Normal And Breast Cancer Cell ...mentioning

confidence: 99%

“…Specific HER2-enriched Raman fingerprints have not been exhaustively investigated so far and, even in the positive cases, the results are poor or deprived of biophysics characterization. In this context, only a comparative study conducted on the efficacy of lapatinib, a tyrosine kinase inhibitor reports how HER2 expression impacts the Raman fingerprint in triple negative or HER2 + BC cell lines [20,48].…”

Section: Generation and Characterization Of Her2-silenced Skbr3 Cells...mentioning

confidence: 99%

Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines

Spaziani,

Esposito,

Barisciano

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Background Breast cancer (BC) is a heterogeneous neoplasm characterized by several subtypes. One of the most aggressive with high metastasis rates presents overexpression of the human epidermal growth factor receptor 2 (HER2). A quantitative evaluation of HER2 levels is essential for a correct diagnosis, selection of the most appropriate therapeutic strategy and monitoring the response to therapy. Results In this paper, we propose the synergistic use of SERS and Raman technologies for the identification of HER2 expressing cells and its accurate assessment. To this end, we selected SKBR3 and MDA-MB-468 breast cancer cell lines, which have the highest and lowest HER2 expression, respectively, and MCF10A, a non-tumorigenic cell line from normal breast epithelium for comparison. The combined approach provides a quantitative estimate of HER2 expression and visualization of its distribution on the membrane at single cell level, clearly identifying cancer cells. Moreover, it provides a more comprehensive picture of the investigated cells disclosing a metabolic signature represented by an elevated content of proteins and aromatic amino acids. We further support these data by silencing the HER2 gene in SKBR3 cells, using the RNA interference technology, generating stable clones further analysed with the same combined methodology. Significant changes in HER2 expression are detected at single cell level before and after HER2 silencing and the HER2 status correlates with variations of fatty acids and downstream signalling molecule contents in the context of the general metabolic rewiring occurring in cancer cells. Specifically, HER2 silencing does reduce the growth ability but not the lipid metabolism that, instead, increases, suggesting that higher fatty acids biosynthesis and metabolism can occur independently of the proliferating potential tied to HER2 overexpression. Conclusions Our results clearly demonstrate the efficacy of the combined SERS and Raman approach to definitely pose a correct diagnosis, further supported by the data obtained by the HER2 gene silencing. Furthermore, they pave the way to a new approach to monitor the efficacy of pharmacologic treatments with the aim to tailor personalized therapies and optimize patients’ outcome.

show abstract

Enhanced characterization of breast cancer phenotypes using Raman micro-spectroscopy on stainless steel substrate

Abstract: Biochemical insights into varying breast cancer (BC) phenotypes can provide a fundamental understanding of BC pathogenesis, while identifying novel therapeutic targets. Raman spectroscopy (RS) can gauge these biochemical differences with...

Cited by 2 publications

References 72 publications

Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines

Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines

Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines

Contact Info

Product

Resources

About